European Drugs And U.S. Executions

Ever since the production of the anesthetic sodium thiopental was discontinued by its U.S. source (Hospira, Inc.), because of concerns over its use in executions, pentobarbital has rapidly become the anesthetic of choice for U.S. executioners.  Alabama, Arizona, Mississippi, Ohio, Oklahoma, South Carolina, and Texas have already carried out executions with it.

Denmark-based Lundbeck is the company whose version of pentobarbital (known as Nembutal) has been used in all these executions, and is slated to be used in at least 6 of the 7 executions scheduled for the rest of June.  (Georgia officials claim they have a different version of pentobarbital, provided to them by Cardinal Health of Ohio; Lundbeck says its drug HAS been sold to Georgia.)

Lundbeck has always objected to the use of its drug in executions, stating things like: “This is fully against what we stand for.”   But prison officials in executing states have been unmoved by this rhetoric.  So now, after some aggressive prompting from campaigning groups like Reprieve, Lundbeck says they are planning to take things up a notch.

SEE THE REST OF THIS POST

Denmark Company Supplies Major U.S. Executioners

“It is not, nor it cannot come to good.” – Hamlet

The European nation of Denmark is about to embark on executions in a big way.  Danish pharmaceutical company Lundbeck has sold pentobarbital to four of the most prolific executing states in the U.S.: Mississippi, Ohio, Oklahoma, and Texas.  These states already have, and will continue to use Lundbeck’s product for executions.  Pentobarbital is emerging as the replacement for sodium thiopental, which was once the drug used in all lethal injections in the U.S., but now has become increasingly hard to get.

Campaigners in Europe have attempted to convince Lundbeck to prevent the drug from winding up in U.S. execution facilities.  Lundbeck has objected, verbally, to the use of its product in executions, telling the New York TimesThis is fully against what we stand for.  We are in the business of improving people’s lives.” But so far Lundbeck has not taken any effective action.

Campaigns to limit exports of sodium thiopental, the drug pentobarbital is replacing, have been successful, albeit after several states already acquired a supply (one state, Georgia, has had its supply confiscated by the DEA).   The UK has banned the drug’s export to the U.S. for executions, and an Italian factory ceased production of the drug entirely.  Governments in Austria and Germany have preemptively warned pharmaceutical companies in their respective countries not to allow sodium thiopental to be exported to the U.S. for executions.

It remains to be seen if Denmark and Lundbeck will ultimately restrict the export of pentobarbital.

Sodium thiopental is a general anesthetic  used in surgical procedures.  Pentobarbital is used for controlling epilepsy.  Life-saving, life-improving drugs, in both cases.  Restricting their availability will do harm to the quality of legitimate health care in the U.S.

I’ve written before about the degrading nature of the death penalty; about how deliberately killing human beings violates our most basic values and thus degrades and damages everyone involved.  That ordinary Americans in need of medical care might suffer because some states insist on killing prisoners is yet more evidence of that.

Maryland Death Penalty Meets Globalization

As Maryland officials attempt to develop a lethal injection protocol that is acceptable to the courts, they have run into an unexpected roadblock – Globalization.   Pharmaceutical companies that produce the drugs used in executions are for the most part multi-national entities, either headquartered in Europe or with large business interests in that region. Capital punishment has been banished in Europe.  Extraditing suspects who might face the death penalty is forbidden, and exporting materials that might be used for executions has now come under intense scrutiny.

Sodium thiopental, the anesthetic Maryland (and all other executing states) had been using as the first drug in its three-drug protocol, was produced by Hospira, at a factory in Italy.  Now, because of controversy over its use in executions, Hospira will no longer make the drug at all.  A generic version of sodium thiopental is manufactured by a subsidiary of Swiss-based Novartis, but that company has announced it will take all steps necessary to prevent its export to the US.  An alternative to sodium thiopental, pentobarbital, which has been used in Oklahoma and may soon be used in Ohio, is made by a company called Lundbeck, based in Denmark.  That company has already gone on record objecting to the use of their drug in executions, and it may only be a matter of time before Lundbeck takes steps to ensure that their drug doesn’t wind up in US execution chambers.

SEE THE REST OF THIS POST